PURE Bioscience to Present at the LD Micro Growth Conference

  PURE Bioscience to Present at the LD Micro Growth Conference

Business Wire

SAN DIEGO -- December 03, 2012

PURE Bioscience, Inc. (NASDAQ: PURE), the creator of the patented silver
dihydrogen citrate (SDC) antimicrobial, today announced that Chief Executive
Officer Michael L. Krall and Chief Financial Officer Peter C. Wulff are
scheduled to present to investors at the 5^th Annual LD Micro Growth
Conference on Thursday, December 6, 2012 at 9:00 a.m. Pacific Time. The
conference is being held in Los Angeles, California at the Luxe Sunset Bel Air
Hotel.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience
products that provide solutions to numerous global health challenges,
including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity
bioscience technologies, including its silver dihydrogen citrate-based
antimicrobials, represent innovative advances in diverse markets and lead
today’s global trend toward industry and consumer use of “green” products
while providing competitive advantages in efficacy and safety. Patented SDC is
an electrolytically generated source of stabilized ionic silver, which
formulates well with other compounds. As a platform technology, SDC is
distinguished from competitors in the marketplace because of its superior
efficacy, reduced toxicity and the inability of bacteria to form a resistance
to it. PURE is headquartered in El Cajon, California (San Diego metropolitan
area). Additional information on PURE is available at www.purebio.com.

Contact:

PURE Bioscience Investor Contact:
LHA
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com
 
Press spacebar to pause and continue. Press esc to stop.